![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright © 2008 by The Endocrine Society Paired-Like Homeodomain Transcription Factors 1 and 2 Regulate Follicle-Stimulating Hormone β-Subunit Transcription through a Conserved cis-Element Department of Pharmacology and Therapeutics (P.L., A.C.D., D.J.B.), McGill University, McIntyre Medical Sciences Building, Montreal, Quebec, Canada H3G 1Y6; and Center for Biomedical Research (P.L., V.K., M.M.S., D.J.B.), Population Council, New York, New York 10021 Address all correspondence and requests for reprints to: Daniel J. Bernard, Ph.D., Department of Pharmacology and Therapeutics, McGill University, McIntyre Medical Sciences Building, 3655 Promenade Sir-William-Osler, Montreal, Quebec, Canada H3G 1Y6. E-mail: daniel.bernard/at/mcgill.ca. Received April 3, 2007; Accepted March 3, 2008. This article has been cited by other articles in PMC.Abstract Paired-like homeodomain transcription factors (PITX) regulate the activity of pituitary hormone-encoding genes. Here, we examined mechanisms through which the family of PITX proteins control murine FSH β-subunit (Fshb) transcription. We observed that endogenous PITX1 and PITX2 isoforms from murine LβT2 gonadotrope cells could bind a highly conserved proximal cis-element. Transfection of PITX1 or PITX2C in heterologous cells stimulated both murine and human Fshb/FSHB promoter-reporter activities, and in both cases, mutation of the critical cis-element abrogated these effects. In homologous LβT2 cells, the same mutation decreased basal reporter activity and greatly reduced activin A-stimulated transcription from murine and human promoter-reporters. Transfecting dominant-negative forms of PITX1 or PITX2C or knocking down PITX1 or -2 expression by RNA interference in LβT2 cells inhibited murine Fshb transcription, confirming roles for endogenous PITX proteins. Both PITX1 and PITX2C interacted with Smad3 (an effector of the activin signaling cascade in these cells) in coprecipitation experiments, and the PITX binding site mutation greatly inhibited Smad2/3/4-stimulated Fshb transcription. In summary, both PITX1 and PITX2C regulate murine and human Fshb/FSHB transcription through a conserved cis-element in the proximal promoter. Furthermore, the data indicate both common and distinct mechanisms of PITX1 and PITX2C action. FSH REGULATES OVARIAN folliculogenesis and is essential for Sertoli cell proliferation and maintenance of sperm quality in the testis. Gonadotrope cells of the anterior pituitary gland secrete FSH and LH. Like other members of the pituitary glycoprotein hormone family, FSH is produced through the heterodimeric assembly of two subunits, α and β, encoded by separate genes. The glycoprotein hormone α-polypeptide is shared by the gonadotropins (FSH and LH), TSH, and chorionic gonadotropin. Unique β-subunits confer biological specificity to the different hormones, and differential regulation of their transcription constitutes one means to selectively control production of each hormone in physiologically relevant contexts (1). The development of the murine gonadotrope-derived cell line LβT2 has provided a powerful in vitro model system for the delineation of mechanisms controlling both cell-specific and hormonally regulated transcription of the gonadotropin subunit genes (2). We and others have used this model to investigate transcriptional regulation of FSHβ subunit (Fshb) promoters from a variety of species, including human, rat, mouse, sheep, and pig (3,4,5,6,7,8,9,10,11,12,13,14). Recent studies have implicated proteins in the PITX/RIEG subfamily of homeodomain transcription factors in both basal and hormonally regulated Fshb subunit expression (8,10). PITX1 (also known as PTX1, BFT, or POTX) is the founding member of the three-gene Paired-like homeodomain transcription factor (PITX) subfamily of bicoid-related proteins. A screen for transcription factors interacting with the pituitary-specific transcription factor Pit-1 (Pou1f1) and binding to a cis-element in the rat proopiomelanocortin (Pomc) promoter (15) led to the cloning of Pitx1. Pitx1 is expressed in the five major hormone-producing cell types of the anterior pituitary in mice and human, although it appears highest in gonadotropes in adulthood (16,17,18,19). Transcription of many pituitary hormone-producing genes, including Cga, Pomc, Gh, Prl, and Tshb, is increased by overexpression of PITX1 in heterologous cell systems (15,20,21,22). These observations suggest a potential role for PITX1 as a pan-pituitary transcriptional regulator. Importantly, transcription of gonadotrope-specific genes, including Lhb, Fshb, and Gnrhr, is also regulated by PITX1 (8,10,22,23,24). The second PITX subfamily member, PITX2 (also known as PTX2, RIEG1, or ARP1) was originally identified through screening of patients with Axenfeld-Rieger syndrome, an autosomal dominant disease causing craniofacial abnormalities (25,26). Three major mRNA isoforms are derived from the PITX2 gene, encoding proteins of 271, 317, and 324 amino acids. PITX2A and PITX2B mRNAs are produced through alternative splicing, whereas PITX2C is transcribed from an alternative promoter (27,28). All three major PITX isoforms are expressed in the anterior pituitary and craniofacial region (18,28). Like PITX1, PITX2 isoforms were shown to act as pan-pituitary transcriptional regulators of hormone encoding genes and are expressed in gonadotropes in adulthood (16,17,18,22,62). PITX2C was implicated in both basal and activin A-stimulated expression of the rat Fshb subunit gene, although PITX2A and PITX2B appeared to play similar roles (8). The third member of the subfamily, PITX3 (PTX3), is not expressed in the anterior pituitary but rather is restricted to dopaminergic neurons of the substantia nigra and ventral tegmentum and to the developing lens (18,29). PITX1 and PITX2 are coexpressed in the anterior pituitary (18,22,30). A comparison of the proteins reveals a high degree of sequence conservation. Their homeodomains are 97% identical, differing by only two amino acids. These similarities extend to their C termini, where they share 70% identity (26,27,30). Their N termini, however, are more divergent. PITX proteins contain a lysine at position 50 of their homeodomains (K50). This is a hallmark of the bicoid-related homeodomain transcription factors, including OTX1, OTX2, and goosecoid (GSC) in vertebrates (31,32). Residue 50 is a critical determinant of DNA-binding specificity of homeodomain proteins, and a lysine at this position predicts that these proteins will bind bicoid-like cis-elements TAATCC, TAAGCT (33,34,35). Indeed, PITX1 binds the bicoid-like motifs: TAAGCC (CE3 element) in the rat Pomc promoter (15) and TAATCT in the ovine, bovine, and rat Lhb promoters (21,24,36). Later, both PITX1 and PITX2 were shown to be equally efficient in binding the CE3 element of the POMC promoter (20,21) and in trans-activating promoters of several pituitary hormone-encoding genes (16,20,21,22). Based on the nearly identical homeodomains and C termini of PITX1 and PITX2, it is not surprising that both can bind the same bicoid-related sites and have similar trans-activation properties in vitro. Recent data suggested a role for PITX1 in basal and GnRH1-stimulated regulation of rat Fshb, acting through a bicoid-like binding site in the proximal promoter, AAATCC (−54/−49) (10). [The PITX1-binding cis-element (AAATCC) identified by Zakaria et al. (10) was indicated to be present between −54/−48 in the rat Fshb promoter. Because the cis-element is 6 bp, we refer to it here as −54/−49.] The involvement of this element in activin-regulated transcription was not investigated, but a second report suggested that PITX2C played a necessary role in both basal and activin A-stimulated transcription of rat Fshb through a cis-element located more distally (−233/−201) (8). [The −230/−199 region of the rat promoter described in Suszko et al. (8) is referred to here as −233/−201. This is based on our identification of a missing base in the sequence reported by Suszko et al. relative to GenBank accession no. M27044 and our mapping of the transcriptional start site using rapid amplification of 5′-cDNA ends.] However, a consensus binding site was not observed in the defined region, nor was an alternative binding sequence mapped. Moreover, whereas gel-shift analyses showed the presence of a specific complex with lysates from HA-PITX2C-transfected cells, the complex was not shifted by an HA antibody making its identity uncertain. Therefore, it is currently unclear whether PITX2C binds directly to DNA in this region to mediate its effects. Nonetheless, a 32-bp deletion encompassing the putative binding site decreased basal and activin A-stimulated transcription in LβT2 cells, suggesting that this promoter region may be required for PITX2C actions, even if it does not bind the protein directly. The work reported here was designed to 1) clarify the apparent differences in binding sites for PITX1 and PITX2C in the Fshb promoter, 2) assess the extent to which PITX regulatory mechanisms are conserved in the Fshb promoters across species (including humans), 3) examine the roles of both PITX1 and PITX2C proteins in basal and activin A-regulated Fshb expression, and 4) determine how PITX proteins and activin signaling mechanisms might intersect to regulate the Fshb gene. Materials and Methods Reagents and constructs Eagle’s MEM was purchased from American Type Culture Collection (Manassas, VA). DMEM with 4.5 g/liter glucose, l-glutamine, and sodium pyruvate was from Mediatech (Herndon, VA). Ham’s F-12/DME media (1:1) with 1.4 g/liter glucose was from Irvine Scientific (Santa Ana, CA). Lipofectamine/Plus, Lipofectamine 2000, gentamicin, and NuPAGE gels were purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) and bovine calf serum were from JRH Biosciences (Lenexa, KS). Horse serum was from Life Technologies, Inc. (Invitrogen, Carlsbad, CA). Human recombinant (rh-) activin A was purchased from R&D Systems (Minneapolis, MN). The anti-PITX1 (SC-18922x) polyclonal antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). SF-1 antirabbit antibody was from Affinity BioReagents (Golden, CO). Anti-Flag M2 monoclonal (F3165), polyclonal anti-Flag antibody (F7425), anti-c-myc (M5546), EZview Red anti-Flag M2 affinity gel, aprotinin, leupeptin, pepstatin, and phenylmethylsulfonyl fluoride were from Sigma Chemical Co. (St. Louis, MO). Deoxynucleotide triphosphates (dNTPs), Taq polymerase, and 5× passive lysis buffer were from Promega (Madison, WI). Protease inhibitor tablets (Complete Mini) was purchased from Roche (Indianapolis, IN). Oligonucleotides were synthesized by IDT (Coralville, IA). Poly(dI)·poly(dC), ECL-plus reagent, and protein marker were purchased from Amersham Biosciences (GE Healthcare, Piscataway, NJ). [γ-32P]ATP was from Perkin-Elmer (Waltham, MA). Pitx1 and Pitx2 SMARTpool small interfering RNAs (siRNAs) were from Dharmacon (Lafayette, CO). The chromatin immunoprecipitation (ChIP) assay reagents and anti-acetyl-histone H3 (Lys9) (07-352) were from Upstate (Lake Placid, NY). The −1990/+1 mFshb-luc reporter, Flag-human Smad2, Flag-human Smad3, and Flag-murine Smad4 expression constructs were described previously (5,11). The −199/+1 of the murine Fshb promoter was PCR amplified from −1990/+1 mFshb-luc and ligated into pGL3-Basic to make −199/+1 mFshb-luc. The −1028/+7 hFSHB-luc reporter was described previously (11), and PCR was used to make 5′ deletions thereof in pGL3-Basic. The PITX-binding element (PBE) mutation (AAATCC to AggTCg) in murine and human FSHB-luc reporters was produced by site-directed mutagenesis using the QuikChange protocol (Stratagene, La Jolla, CA). Mouse Pitx1, Pitx2a, Pitx2b, and Pitx2c cDNAs were generated by RT-PCR from LβT2 mRNA and ligated into pcDNA3.0 (Invitrogen) by previously described methods (5). The dominant-negative mutants were generated by site-directed mutagenesis. Flag-PITX1 expression vector was constructed by amplifying the PITX1 cDNA and ligating it in-frame with a vector containing the Flag epitope at the N terminus. Myc-PITX1 was generated by adding the myc epitope to the 5′ end of the forward PCR primer. The identities of all constructs were verified by DNA sequencing (Genewiz, South Plainfield, NJ). Primers for cloning and mutagenesis are shown in supplemental Table 1 (published as supplemental data on The Endocrine Society’s Journals Online web site at http://endo.endojournals.org). Cell culture, transfection, and reporter assays LβT2 cells were provided by Dr. Pamela Mellon (University of California, San Diego, CA) and were cultured as described previously (5,11). HepG2 cells were obtained from American Type Culture Collection and were cultured in MEM/10% FBS. CHO and CV-1 cells were provided by Dr. Patricia Morris (Population Council, New York, NY). CHO cells were cultured in F-12/DME with low glucose, 5% horse serum, and 2.5% bovine calf serum. CV-1 cells were cultured in DMEM/10% FBS. For the reporter experiments, LβT2 and HepG2 cells were plated in 24-well plates at a density of 1–2 × 105 cells per well approximately 36 h before transfection. Cells were transfected with Lipofectamine 2000. Reporter and expression plasmids were transfected at 450 ng and 200–300 ng per well, respectively. In experiments with ligand treatment, cells were washed in serum-free DMEM or 1× PBS and then treated with 1 nm activin A in serum-free DMEM or with DMEM alone (control) for about 24 h. Lysates were collected the following day. Luciferase assays were performed on a Luminoskan Ascent luminometer (Thermo Labsystems, Franklin, MA) using standard reagents. Several vectors typically used for transfection efficiency controls were regulated by the majority of our manipulations (data not shown) and were therefore excluded from the analyses. Measures of protein concentrations showed no differences in cell viability with the different treatments. To assess knockdown of endogenous PITX1 in LβT2 cells, cells were transfected with the Pitx1 siRNA pool using a reverse transfection protocol (37). Briefly, 10 nm siRNA was combined with Lipofectamine/Plus reagent as per the manufacturer’s protocol. The siRNA-lipid mix was added to 1.5 × 106 cells in suspension and immediately plated into one well of a six-well plate. After 6 h, medium was replaced and cell lysates collected 72 h later in RIPA buffer with protease inhibitor (Roche). CV-1 cells were plated in 12-well plates and transfected using the calcium phosphate method. CHO cells were plated in 10-cm dishes for nuclear protein extraction (for gel shifts) and immunoprecipitation experiments and were transfected when 70–80% confluent with 8 μg of the total plasmid-DNA using Lipofectamine following the manufacturer’s instructions. EMSA Nuclear extracts were collected and gel shift experiments performed as described previously (11) with the following modifications: 0.5–1 μg poly(dI)·poly(dC) was used as nonspecific competitor, and gels were run for 2.5–3 h. DNA precipitation and immunoblot assays Whole-cell lysates were prepared from LβT2 cells and assays performed as described previously (11) with the following modification: proteins bound to biotinylated probes were isolated using Dynabeads M-280 streptavidin (Dynal; Invitrogen). Briefly, 1/10 of each lysate was used in a DNA precipitation assay with 100 ng biotinylated double-stranded, murine Fshb 61/−40 wild-type (WT) and mutant (Mut) (see supplemental Table 1) probes. After washes, bound proteins were eluted from the beads, separated on 10% NuPAGE Bis-Tris gels, transferred to Protran nitrocellulose (Schleicher & Schuell, Keene, NH), and sequentially probed with PITX1, PITX2 (P2Y4, a gift from Tord Hjalt, Lund University, Lund, Sweden), and anti-SF1. The details of the immunoblot protocol have been described previously (5). Southwestern blot Nuclear extracts were separated on a 12% NuPAGE Bis-Tris gel in triplicate and transferred to Protran. The filter was cut into sections for Western blotting or for Southwestern analyses. For the latter, blots were incubated in binding buffer [20 mm HEPES (pH 7.9), 50 mm KCl, 1 mm dithiothreitol, 10% glycerol, and 0.1% Nonidet P-40] for 45 min at room temperature, followed by a 3-h incubation in the same buffer containing 5% nonfat milk. Blots were then hybridized overnight at 4 C with radiolabeled murine −61/−40 or −232/−200 Fshb probes (2 × 106 cpm/ml) in binding buffer plus 0.5% nonfat milk and 1 μg/ml salmon sperm DNA. Blots were washed twice (30 min each) in binding buffer at room temperature and then exposed to x-ray film. ChIP assay ChIP assays were performed following the manufacturer’s protocol (Upstate). Briefly, LβT2 cells were grown in 10-cm dishes and either used directly or after transfection. In the latter case, cells were transfected with either −1990 mFshb-luc WT or PBEmut reporter along with Flag-PITX1. In all cases, DNA was cross-linked to protein with 1% formaldehyde for 15 min at 37 C. Cells were washed with PBS, scraped, and resuspended in ChIP lysis buffer. The samples were sonicated six times for 5 sec each at power setting 1.5 (model 100; Fisher Scientific, Ottawa, Ontario, Canada). Sonicated samples were diluted with dilution buffer, precleared with protein G-agarose beads, and then incubated with specific antibodies (PITX1 or Flag) overnight at 4 C. The immune complexes were collected the next day using protein G-agarose beads, and DNA was eluted and cleaned as described in the protocol. For examination of the endogenous gene, −199 to +1 and −505 to −305 of the murine Fshb promoter were amplified using the primers indicated in supplemental Table 1. For analysis of transfected promoters, immunoprecipitated samples were quantified in duplicate by real-time quantitative PCR using SYBR Green qPCR Master Mix (Invitrogen), and the primers are indicated in supplemental Table 1. Input samples were diluted 1/100, whereas undiluted IgG and antibody samples were used for amplification. Quantification was performed by subtracting the calculated chromatin concentration (using the relative standard curve method) of the IgG sample from its corresponding Flag sample and dividing by the concentration of their input sample. Co-immunoprecipitation assays CHO cells were cotransfected with the indicated expression constructs. In some experiments, cells were stimulated or not with 1 nm activin A for 1 h before harvesting. Cells were harvested and lysed in 50 mm Tris-HCl (pH 7.5), 150 mm NaCl, 1 mm EDTA, and 1% Triton X-100. After the removal of the insoluble material by centrifugation, Bradford assays (Bio-Rad) were performed to determine protein concentrations. Equivalent amounts of protein in each condition were combined with a 40-μl gel volume of anti-FLAG M2 agarose affinity beads [prewashed and equilibrated with Tris-buffered saline: 50 mm Tris-HCl (pH 7.5) and 150 mm NaCl] and incubated overnight at 4 C. Beads were washed three times with Tris-buffered saline and collected by centrifugation. After aspirating the final wash, the affinity beads were resuspended in 3× Flag peptide at a concentration of 150 μg/ml and incubated for 1 h at 4 C. Eluted proteins were collected and run on NuPAGE gels along with whole-cell extracts and probed with the indicated antibodies as described previously (5). Statistics The data from three to five replicate experiments were pooled for statistical analyses. Luciferase reporter data are presented as fold change from the control condition (set to 1) in each experiment. Differences between means were compared using one- or two-way ANOVA, followed by post hoc tests where appropriate (Systat 10.2, Richmond, CA). In some experiments, data were log transformed when the variances were unequal between groups. In all the experiments, significance was assessed relative to P < 0.05. Results PITX proteins regulate basal Fshb/FSHB transcription through a proximal PITX/bicoid-like binding element Previous studies using rat, bovine, and porcine Fshb promoter-reporters showed that overexpression of PITX family proteins could stimulate basal transcription in heterologous cell lines (8,9,10,22). Here, we examined the effects of murine PITX1 overexpression on murine −1990/+1 Fshb-luc promoter-reporter (5,11) activity in heterologous HepG2 cells. Western blot analyses confirmed that these cells do not express PITX1 or PITX2 endogenously, whereas these proteins are abundantly expressed in homologous LβT2 cells (Fig. 1A 1A)
To determine specific cis-elements through which these proteins stimulate transcription, we examined the effects of transfected PITX1 and PITX2C on a series of 5′ truncations of the murine Fshb promoter. Although we identified several potential PITX-binding sites in silico (e.g. −1592/−1587, −963/−958, −941/−936, and −53/−48) (21,34,40), truncating the promoter from −1990 to −257 did not significantly affect PITX1- or PITX2C-stimulated transcription in HepG2 cells (data not shown). These results suggested that both proteins mediated their effects principally through a proximal promoter element between −257 and +1. Previous studies indicated that PITX1 acts through a cis-element, AAATCC, at −54/−49 of the rat Fshb promoter (10), whereas PITX2C was reported to exert its effects through a less well-delineated element between −233/−201 in the same gene (8). The promoter is highly conserved between mice and rats (Fig. 1C 1C). We then examined whether the mechanisms observed in mouse extended to the human promoter. We transfected human FSHB promoter-reporter constructs of varying lengths along with PITX1 or PITX2C into HepG2 cells. Both proteins significantly and similarly activated the human reporter, although there was variation in fold stimulation among the different constructs (supplemental Fig. S1). The PITX element identified in rat and mouse is perfectly conserved in human and is contained within the −126/+7 interval (at −65/−60; Fig. 1C 1C). PITX proteins can bind directly to the proximal PITX cis-element To show that PITX proteins can bind to the proximal cis-element (PBE) in the murine promoter, we first performed gel shift analyses with nuclear protein extracts from CHO cells overexpressing PITX1 or PITX2C. CHO cells do not express PITX proteins endogenously (41,42) (see also Fig. 2C 2C,
PITX proteins have been shown to homodimerize (42,43,44), and we confirmed this here (Fig. 2B 2B), Gel shift analyses with nuclear extracts from PITX2C-overexpressing CHO cells (Fig. 2A 2A, To confirm that endogenous PITX proteins can also bind to the PBE, we first performed DNA precipitation assays with LβT2 whole-cell protein lysates and biotinylated −61/−40 probe (−61/−40 WT). A second biotinylated probe containing the PBE mutation (−61/−40 Mut) was included as a control. The precipitated protein complexes were subjected to immunoblot analyses using PITX1- and PITX2-specific antibodies. The results demonstrated that endogenous PITX1 (Fig. 2D 2D, A single PBE exists within the −61/−40 promoter region The data above suggested that homodimeric PITX proteins might form complexes with the −61/−40 probe. Although only one PBE appears to be located within this interval, previous data indicate that binding of one member of the dimer to a high-affinity site may facilitate binding of the second protein to an adjacent low-affinity site (45). To assess whether additional sequences outside of the core PBE contributed to higher-order complex binding, we performed gel shifts with the WT −61/−40 probe and nuclear extracts from PITX1-overexpressing CHO cells and competed binding with unlabeled probes containing 2-bp mutations spanning the −61/−40 interval (Fig. 3A 3A).
PITX proteins do not bind to the putative PITX2C-binding region The functional data in Fig. 1B 1B
The proximal PBE is required for activin A-mediated transcriptional regulation An earlier report indicated a role for the proximal PBE in both basal and GNRH1-stimulated activity of the rat Fshb promoter (10). Because activins are also important positive regulators of Fshb subunit transcription (3,4,5,6,7,8,9,11,12,14,48) and because PITX2C was previously shown to participate in activin A-mediated regulation of the rat Fshb gene (8), we explored the role of the PBE in activin A-stimulated murine Fshb promoter activity. LβT2 cells were transfected with −1990/+1 mFshb-luc or a similar construct containing the PBE mutation [−1990/+1 mFshb PBEmut-luc; see Fig. 3A 3A
We showed previously that the human −1028/+7 FSHB-luc reporter was activin A responsive in LβT2 cells, although significantly less so than a murine promoter of comparable length (11). Here, we compared basal and activin A-stimulated activity of the WT human reporter with one containing the PBE mutation (Fig. 5B 5B). PITX proteins regulate murine Fshb promoter activity in homologous cells The data in Fig. 5 5 Previous studies showed that mutations of lysine 50 (K50) of the homeodomain in PITX2 produced dominant-negative forms of the protein (41). For example, the DNA-binding-deficient PITX2A mutant, K88E, suppressed prolactin (Prl) promoter activity when overexpressed in homologous GH3 somatolactotrope cells. The mutant protein was argued to produce this effect via dimerization with endogenous PITX proteins bound to PBEs in the Prl promoter, inhibiting their trans-activation function (41,43). With this framework in mind, we produced DNA-binding-deficient forms of murine PITX2C by mutating K141 to glutamic acid (K141E, analogous to the K88E mutation in PITX2A) or to alanine (K141A) and subsequently produced murine PITX1-K139A. Using gel shift analyses with the −61/−40 Fshb probe, we confirmed that these proteins had greatly impaired DNA-binding ability (supplemental Fig. S3C), even although they were expressed at WT levels (Fig. S3, A and B). We also showed that they inhibited WT PITX2C function in heterologous cells (Fig. S3D). We next transfected the WT or dominant-negative constructs into LβT2 cells along with −1990/+1 mFshb-luc and treated cells with activin A for 24 h. The WT PITX2C mildly increased basal activity, whereas the K141E and K141A mutants impaired basal activity by 43 and 59%, respectively (Fig. 6A 6A).
To confirm the requirement of endogenous PITX proteins in basal and activin A-regulated mFshb transcription, we knocked down protein expression using Pitx1 and Pitx2 siRNA pools in LβT2 cells, after first validating their efficacy and specificity (supplemental Figs. S5 and S6). The Pitx1 and Pitx2 siRNAs inhibited basal Fshb reporter activity by 49 and 65%, respectively (Fig. 6C 6C). PITX proteins physically interact with Smad3 We next explored whether and how PITX proteins interface with the activin signaling transduction cascade. We showed previously that activins stimulate the formation of Smad2/3/4 complexes that bind to a Smad-binding element (SBE) in the murine Fshb promoter at −266/−259 (11). This binding is critical for both the acute and tonic effects of activins on transcription. Therefore, we examined whether PITX proteins interact with Smads, providing a potential link between the PBE and the SBE. CHO cells were cotransfected with PITX1 (Fig. 7A 7A)
PITX2C and Smad3 were previously shown to function synergistically and confer activin responsiveness to the rat Fshb promoter in heterologous cells (8). We have been unable to replicate this finding and in fact observe that coexpression of Smad3 slightly inhibits PITX2C stimulation of murine Fshb reporter activity in HepG2 cells (see supplemental Fig. S7B). The PBE is required for Smad-stimulated promoter activity Finally, we examined the role of the PBE in Smad-regulated promoter activity. We previously showed that Smads 2, 3, and 4 in combination synergistically stimulate murine Fshb promoter activity (11), and we confirmed that observation again here (Fig. 7C 7C). Discussion PITX1 and PITX2C were previously shown to regulate basal and hormone-dependent transcription of the Fshb subunit gene, but through distinct mechanisms (8,10). The results presented here clarify these apparently discrepant findings and significantly advance our understanding of how PITX proteins regulate the Fshb gene. We show that both PITX1 and PITX2C mediate their effects through a common cis-element (PBE) in the proximal Fshb promoter. This PBE is conserved in all mammalian species in which the gene has been characterized thus far (Fig. 1C 1C) A proximal cis-element mediates regulation of the Fshb by PITX proteins PITX1 and PITX2 isoforms act as pan-pituitary transcriptional activators but at the same time contribute to the mechanisms of cell-restricted expression of various pituitary hormone-encoding genes (15,21,22,50,51). Our results show that both PITX1 and PITX2C can stimulate murine Fshb and human FSHB promoter activities in heterologous cells. In contrast, overexpression of these proteins in homologous LβT2 cells has little or no effect on basal transcription. These observations are comparable to those from a previous report where PITX1 overexpression stimulated rat Fshb promoter activity in heterologous GGH3-1 cells but not in LβT2 cells (10). However, a second study showed that PITX2 isoforms, especially PITX2C, stimulated basal activity of the rat Fshb promoter in LβT2 cells (8). An explanation for the contrasting results is not immediately obvious; however, several studies using different PITX-sensitive promoters in homologous cell lines have reported little or no potentiation of transcription when endogenous PITX1 and PITX2 protein levels are not limiting (20,41,46,50). Our data indicate that both PITX1 and PITX2C affect Fshb transcription by direct binding to the cis-element, AAATCC, in the proximal promoter. Although not identical to the consensus binding site for homeodomain proteins within the K50 class, TAATCC (31,34), the element is perfectly conserved in sequence and relative location in the Fshb/FSHB promoters across mammalian species (Fig. 1C 1C) That both PITX1 and PITX2C (and other PITX2 isoforms; see Ref. 62) bind to the PBE is not surprising given the high conservation (97%) of their homeodomains. However, using 5′ promoter deletions and gel shift analyses, a previous report identified a PITX2C-binding region between −233/−201 in the rat Fshb gene (8). In this case, a well-delineated cis-element was not characterized (49), nor was a consensus PITX-binding site observed therein. Nonetheless, deleting a comparable region, −232/−200, of the mouse promoter did not alter PITX2C (or PITX1) responsiveness in heterologous cells in our analyses. In addition, PITX2C did not bind to this region of the rat or murine promoters in gel shift or Southwestern blot analyses in our hands. This was true whether we used our own or previously described gel shift methods (8). Instead, both exogenous PITX2C and at least three endogenous PITX2 isoforms (likely PITX2A and two isoforms of PITX2C; see Ref. 62) could clearly bind the PBE at −53/−48, and exogenous PITX proteins exerted the bulk of their actions on murine and human promoter activity via binding to this site. Thus, we conclude that the more distal region of the Fshb promoter does not mediate the direct effects of PITX proteins on transcription. It is possible, however, that the more distal region is important for regulation of Fshb transcription by activins, and this may have impacted previous interpretations (8). Deletion of this region in the context of a −338 rat Fshb luciferase reporter decreased both Smad3 and activin A responsiveness in LβT2 cells (8). A second study similarly showed a role for −230/−194 in follistatin- (and by inference activin B)-mediated regulation of murine Fshb in these cells (6). Thus, whereas we conclude that this part of the promoter does not bind PITX proteins directly, it might be important for activin regulation and could bind proteins that associate with PITX factors binding more proximally. PITX proteins may bind the Fshb promoter as dimers Our gel shift assays suggest that PITX proteins may bind to the Fshb promoter as monomers (PITX1) or dimers (PITX1 and PITX2C). Indeed, previous analyses of several promoters show that PITX1 and PITX2 can bind in different multimeric forms (42,43,46,53). Consistent with these observations, previous biochemical analyses showed that PITX1 and PITX2 isoforms can homodimerize (42,44). We confirmed these observations here and also showed for the first time, to our knowledge, that PITX1 and PITX2 proteins can heterodimerize (Fig. 2B 2B Previous analyses suggest that K50 mutants exert their dominant-negative activity by dimerizing with WT proteins. Whereas the mechanism of inhibition is not completely understood, mutations to K50 appear to increase the association between the homeodomain (DNA-binding domain) and the C terminus (putative activation domain), and the interaction of these two domains has been associated with decreased DNA binding and trans-activation (43). Similarly, we also observe that both PITX1 and PITX2C K50 mutants in heterologous cells have no effect on their own but can dose-dependently antagonize the stimulatory effect of WT. We predict that the Lys to Ala mutants similarly inhibit basal reporter activity in homologous LβT2 cells by dimerizing with endogenous PITX proteins bound to the Fshb promoter. We observed only a minor inhibition of WT PITX1 binding to the PBE in the presence of K139A (data not shown), so we predict that the antagonism is principally through disruption of a trans-activation function of WT proteins. It is also possible that these mutants inhibit basal activity in LβT2 cells by competing for binding to limiting endogenous cofactors, although we currently have no direct evidence of this. Indeed, if this were a mechanism of antagonism, then overexpressed WT PITX proteins might be expected to produce the same inhibitory effects on basal activity, which they did not. Endogenous PITX proteins regulate Fshb transcription Although previous reports have shown that overexpressed PITX1 and PITX2 isoforms can stimulate Fshb subunit transcription in heterologous cells, none have confirmed a role for endogenous PITX proteins in this process (8,10,22). Pitx1 or Pitx2 knockout mice have been generated, but both models have developmental defects that preclude an assessment of PITX proteins in FSH regulation in adulthood (54,55,56,57,58). The present and previous work (10) demonstrates that endogenous PITX proteins can bind this site, but this does not preclude the binding of other homeodomain proteins expressed in gonadotrope cells (38). Therefore, based on previous reports, one could not conclude that PITX proteins were endogenous regulators of the Fshb subunit. Here, we show that endogenous PITX1 and three PITX2 isoforms can bind to the PBE and that PITX1 binds the murine Fshb promoter in cells. Moreover, transfection of PITX1 and PITX2C dominant-negative proteins (K50A mutants) or knockdown of endogenous PITX proteins using RNA interference inhibited both basal and activin A-stimulated Fshb transcription. The effect of the Pitx1 and Pitx2 siRNA pools on the activin response was observed only when the two were used in combination, and the overall effect was modest (~25%) relative to the effects of the PBE mutation (~80%). These results may reflect an inability of the siRNAs to inhibit completely PITX protein expression in LβT2 cells (e.g. supplemental Fig. S5A). Alternatively, a different homeodomain protein may bind the PBE in the absence of PITX proteins (38), compensating for their loss. Even though PITX1 and PITX2C were functionally similar in the majority of our analyses, differences in their binding characteristics could have functional consequences. This is most clearly demonstrated in LβT2 cells where WT PITX1 transfection had no effect on basal activity but antagonized the activin A response. In contrast, WT PITX2C affected only the fold activin A response by virtue of its small stimulation of basal activity (this was also the case for PITX2A and PITX2B; Fig. 6A 6A PITX proteins regulate activin signaling to the Fshb promoter Fshb transcription is potently up-regulated by activins in many species including mice (3,4,5,7,8,11). The PBE appears critical for this response. Mutation of this element greatly inhibits activin A responsiveness, particularly of the murine Fshb reporter. This does not reflect a generalized inhibition of reporter responsiveness because fold stimulation of the rat and murine Fshb promoter activity by GNRH1 is unaltered by the same mutation (10) (data not shown). Mutation of the PITX-binding site in the Lhb promoter similarly inhibits basal, but not GNRH1-stimulated, reporter activity in LβT2 cells (24). We and others have shown that activin A stimulates the formation of Smad2/3/4 complexes that interact with a SBE at −266/−259 in the murine Fshb reporter (4,8,11). Transfection of these Smads in LβT2 cells stimulates reporter activity in ligand-independent fashion, and mutating the SBE blocks this response (11). Here, mutation of the PBE also significantly blunted the effects of transfected Smads on reporter activity. In addition, we observed for the first time that Smad3 could interact with both PITX1 and PITX2C in transfected mammalian cells. A previous report showed direct interactions between Smads 2, 3, and 4 and PITX1 in glutathione-S-transferase pull-down assays (36). Suszko et al. (59) recently showed an interaction between Smad3 and PITX2C in cells and Smad3 and Smad2 with PITX2A and PITX2C in yeast. They did not report any data for Smad4 or PITX1, nor did they show PITX2C/Smad2 interactions in mammalian cells. However, they showed that the homeodomain of PITX2C was required for the interaction with Smads 2 and 3 in yeast (59). We failed to detect interactions between PITX1 or PITX2C with Smads 2 and 4 in CHO cells. The reason for the discrepant results is not clear, although differences in the assay systems used are likely involved. Nonetheless, these data suggest a model in which PITX proteins constitutively bound to the proximal Fshb promoter regulate basal transcription in gonadotrope cells. Upon activin stimulation, Smad2/3/4 complexes bind the SBE and perhaps other promoter elements (6,60). Smad3 in these complexes could directly interact with PITX proteins bound more proximally. This may alter the DNA conformation in such a way as to increase transcriptional activation by Smads or facilitate their interaction with the basal transcriptional machinery. Alternatively, the Smad-PITX interaction may help stabilize the binding of either or both complexes to their respective cis-elements. The SBE is present in rodent Fshb promoters but is absent in other species, including humans (49). Therefore, this model may not fully explain the role of PITX proteins in activin-regulated transcription; however, Smads may interact with alternate promoter elements in other species (6), suggesting that Smad-PITX interactions may be conserved and important in Fshb regulation. In conclusion, our data suggest that the PITX family of proteins may form part of a cell-restricted transcriptional complex that confers both basal and activin responsiveness to the Fshb promoter in gonadotrope cells. Indeed, PITX proteins have been shown to cooperate with the cell-restricted transcriptional regulators SF-1 and Pit-1 to regulate Lhb and Prl promoter activities in gonadotrope and lactotrope cells, respectively (20,61). The clear delineation of the PBE and proteins binding to it provides the basis for understanding more fully the mechanisms of gonadotrope-restricted expression of the Fshb/FSHB gene. [Supplemental Data]
Acknowledgments We thank Drs. Y. Chen, T. Hjalt, J. Massague, P. Mellon, P. Morris, E. Robertson, and T. Woodruff for generously providing cell lines and reagents. Some of the cell culture work was performed in the Cell and Tissue Culture Core Facility of the Population Council under the direction of Dr. Patricia Morris and with the assistance of Marion Davis and Catherine Rapelje. We are also thankful to Dr. K. Lee for critically reading an earlier version of the manuscript. Footnotes This research was supported by National Institute of Child Health and Human Development/National Institutes of Health R01 HD047794 to D.J.B. P.L. was partially supported by the F. M. Kirby Foundation. Disclosure Statement: The authors have nothing to disclose. First Published Online March 13, 2008 Abbreviations: ChIP, Chromatin immunoprecipitation; FBS, fetal bovine serum; Mut, mutant; PBE, PITX-binding element; PITX, Paired-like homeodomain transcription factor; SBE, Smad-binding element; siRNA, small interfering RNA; WT, wild type. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Rev Reprod. 1999 May; 4(2):117-24.
[Rev Reprod. 1999]Development. 1996 Oct; 122(10):3319-29.
[Development. 1996]Endocrinology. 2001 Jun; 142(6):2284-95.
[Endocrinology. 2001]Mol Endocrinol. 2005 Jan; 19(1):237-54.
[Mol Endocrinol. 2005]Mol Endocrinol. 2004 Mar; 18(3):606-23.
[Mol Endocrinol. 2004]Mol Endocrinol. 2004 May; 18(5):1158-70.
[Mol Endocrinol. 2004]Genes Dev. 1996 May 15; 10(10):1284-95.
[Genes Dev. 1996]Mol Cell Endocrinol. 1998 May 25; 140(1-2):31-6.
[Mol Cell Endocrinol. 1998]Mol Endocrinol. 2005 Jul; 19(7):1893-903.
[Mol Endocrinol. 2005]J Clin Endocrinol Metab. 1999 Jun; 84(6):2212-20.
[J Clin Endocrinol Metab. 1999]Endocrinology. 1999 Mar; 140(3):1416-22.
[Endocrinology. 1999]Expert Rev Mol Med. 2005 Nov 8; 7(25):1-17.
[Expert Rev Mol Med. 2005]Nat Genet. 1996 Dec; 14(4):392-9.
[Nat Genet. 1996]Proc Natl Acad Sci U S A. 1998 Apr 14; 95(8):4573-8.
[Proc Natl Acad Sci U S A. 1998]Hum Mol Genet. 1997 Mar; 6(3):457-64.
[Hum Mol Genet. 1997]J Clin Endocrinol Metab. 1999 Jun; 84(6):2212-20.
[J Clin Endocrinol Metab. 1999]J Clin Endocrinol Metab. 1999 Jun; 84(6):2212-20.
[J Clin Endocrinol Metab. 1999]Neuroendocrinology. 2000 May; 71(5):277-86.
[Neuroendocrinology. 2000]Mamm Genome. 1999 Feb; 10(2):197-200.
[Mamm Genome. 1999]Nat Genet. 1996 Dec; 14(4):392-9.
[Nat Genet. 1996]Proc Natl Acad Sci U S A. 1998 Apr 14; 95(8):4573-8.
[Proc Natl Acad Sci U S A. 1998]Mol Endocrinol. 2002 Aug; 16(8):1840-52.
[Mol Endocrinol. 2002]Mol Endocrinol. 2003 Mar; 17(3):318-32.
[Mol Endocrinol. 2003]Mol Endocrinol. 2004 Mar; 18(3):606-23.
[Mol Endocrinol. 2004]J Mol Endocrinol. 2006 Feb; 36(1):201-20.
[J Mol Endocrinol. 2006]Mol Endocrinol. 2004 Mar; 18(3):606-23.
[Mol Endocrinol. 2004]J Mol Endocrinol. 2006 Feb; 36(1):201-20.
[J Mol Endocrinol. 2006]Mol Endocrinol. 2007 Apr; 21(4):963-71.
[Mol Endocrinol. 2007]J Mol Endocrinol. 2006 Feb; 36(1):201-20.
[J Mol Endocrinol. 2006]J Mol Endocrinol. 2006 Feb; 36(1):201-20.
[J Mol Endocrinol. 2006]Mol Endocrinol. 2004 Mar; 18(3):606-23.
[Mol Endocrinol. 2004]Mol Endocrinol. 2004 Mar; 18(3):606-23.
[Mol Endocrinol. 2004]Mol Endocrinol. 2003 Mar; 17(3):318-32.
[Mol Endocrinol. 2003]Endocrinology. 2004 Nov; 145(11):4866-79.
[Endocrinology. 2004]Mol Endocrinol. 2002 Aug; 16(8):1840-52.
[Mol Endocrinol. 2002]Neuroendocrinology. 2000 May; 71(5):277-86.
[Neuroendocrinology. 2000]Mol Endocrinol. 2004 Mar; 18(3):606-23.
[Mol Endocrinol. 2004]Mol Endocrinol. 1998 Mar; 12(3):428-41.
[Mol Endocrinol. 1998]Biochemistry. 2005 May 24; 44(20):7497-511.
[Biochemistry. 2005]Cell. 1994 Jul 29; 78(2):211-23.
[Cell. 1994]Mol Endocrinol. 2002 Aug; 16(8):1840-52.
[Mol Endocrinol. 2002]Mol Endocrinol. 2003 Mar; 17(3):318-32.
[Mol Endocrinol. 2003]J Biol Chem. 2001 Jun 22; 276(25):23034-41.
[J Biol Chem. 2001]J Biol Chem. 2002 Jul 12; 277(28):25001-10.
[J Biol Chem. 2002]J Biol Chem. 2002 Jul 12; 277(28):25001-10.
[J Biol Chem. 2002]Mol Cell Biol. 2003 Mar; 23(6):1968-82.
[Mol Cell Biol. 2003]J Biol Chem. 2002 Jul 19; 277(29):26200-7.
[J Biol Chem. 2002]BMC Mol Biol. 2008 Mar 28; 9():31.
[BMC Mol Biol. 2008]EMBO J. 1998 Oct 15; 17(20):5998-6009.
[EMBO J. 1998]Mol Cell Biol. 2000 Oct; 20(20):7673-84.
[Mol Cell Biol. 2000]Gene Expr. 2001; 9(6):265-81.
[Gene Expr. 2001]Bioessays. 2005 Sep; 27(9):904-13.
[Bioessays. 2005]Mol Endocrinol. 2003 Mar; 17(3):318-32.
[Mol Endocrinol. 2003]Mol Endocrinol. 2002 Aug; 16(8):1840-52.
[Mol Endocrinol. 2002]Endocrinology. 2001 Jun; 142(6):2284-95.
[Endocrinology. 2001]Mol Endocrinol. 2005 Jan; 19(1):237-54.
[Mol Endocrinol. 2005]Mol Endocrinol. 2004 Mar; 18(3):606-23.
[Mol Endocrinol. 2004]Mol Endocrinol. 2004 May; 18(5):1158-70.
[Mol Endocrinol. 2004]J Mol Endocrinol. 2006 Feb; 36(1):201-20.
[J Mol Endocrinol. 2006]Mol Endocrinol. 2002 Aug; 16(8):1840-52.
[Mol Endocrinol. 2002]J Biol Chem. 2001 Jun 22; 276(25):23034-41.
[J Biol Chem. 2001]Mol Cell Biol. 2003 Mar; 23(6):1968-82.
[Mol Cell Biol. 2003]Mol Endocrinol. 2002 Aug; 16(8):1840-52.
[Mol Endocrinol. 2002]J Mol Endocrinol. 2006 Feb; 36(1):201-20.
[J Mol Endocrinol. 2006]Mol Endocrinol. 2003 Mar; 17(3):318-32.
[Mol Endocrinol. 2003]J Mol Endocrinol. 2006 Feb; 36(1):201-20.
[J Mol Endocrinol. 2006]Mol Endocrinol. 2003 Mar; 17(3):318-32.
[Mol Endocrinol. 2003]Mol Endocrinol. 2002 Aug; 16(8):1840-52.
[Mol Endocrinol. 2002]Mol Cell Endocrinol. 2006 Mar 9; 247(1-2):103-15.
[Mol Cell Endocrinol. 2006]Genes Dev. 1996 May 15; 10(10):1284-95.
[Genes Dev. 1996]Mol Endocrinol. 1998 Mar; 12(3):428-41.
[Mol Endocrinol. 1998]Neuroendocrinology. 2000 May; 71(5):277-86.
[Neuroendocrinology. 2000]Endocrinology. 2002 Aug; 143(8):2839-51.
[Endocrinology. 2002]J Neuroendocrinol. 2006 Sep; 18(9):633-42.
[J Neuroendocrinol. 2006]Mol Cell Biol. 2000 Oct; 20(20):7673-84.
[Mol Cell Biol. 2000]Biochemistry. 2005 May 24; 44(20):7497-511.
[Biochemistry. 2005]Mol Cell Endocrinol. 2006 Mar 9; 247(1-2):103-15.
[Mol Cell Endocrinol. 2006]J Cell Biol. 2001 Feb 5; 152(3):545-52.
[J Cell Biol. 2001]BMC Mol Biol. 2008 Mar 28; 9():31.
[BMC Mol Biol. 2008]Mol Endocrinol. 2003 Mar; 17(3):318-32.
[Mol Endocrinol. 2003]Mol Cell Endocrinol. 2006 Mar 9; 247(1-2):103-15.
[Mol Cell Endocrinol. 2006]Mol Endocrinol. 2003 Mar; 17(3):318-32.
[Mol Endocrinol. 2003]Mol Endocrinol. 2004 May; 18(5):1158-70.
[Mol Endocrinol. 2004]J Biol Chem. 2002 Jul 12; 277(28):25001-10.
[J Biol Chem. 2002]Mol Cell Biol. 2003 Mar; 23(6):1968-82.
[Mol Cell Biol. 2003]Gene Expr. 2001; 9(6):265-81.
[Gene Expr. 2001]Mol Cell Biol. 1999 Oct; 19(10):7001-10.
[Mol Cell Biol. 1999]J Biol Chem. 2002 Jul 19; 277(29):26200-7.
[J Biol Chem. 2002]Mol Cell Biol. 2003 Mar; 23(6):1968-82.
[Mol Cell Biol. 2003]Mol Endocrinol. 2003 Mar; 17(3):318-32.
[Mol Endocrinol. 2003]Mol Endocrinol. 2002 Aug; 16(8):1840-52.
[Mol Endocrinol. 2002]Neuroendocrinology. 2000 May; 71(5):277-86.
[Neuroendocrinology. 2000]Development. 1999 May; 126(9):1805-10.
[Development. 1999]Genes Dev. 1999 Feb 15; 13(4):484-94.
[Genes Dev. 1999]J Biol Chem. 2002 Nov 15; 277(46):44408-16.
[J Biol Chem. 2002]J Biol Chem. 2002 Jul 19; 277(29):26200-7.
[J Biol Chem. 2002]Endocrinology. 2001 Jun; 142(6):2284-95.
[Endocrinology. 2001]Mol Endocrinol. 2005 Jan; 19(1):237-54.
[Mol Endocrinol. 2005]Mol Endocrinol. 2004 Mar; 18(3):606-23.
[Mol Endocrinol. 2004]Mol Endocrinol. 2005 Jul; 19(7):1849-58.
[Mol Endocrinol. 2005]Mol Endocrinol. 2003 Mar; 17(3):318-32.
[Mol Endocrinol. 2003]Mol Endocrinol. 2005 Jan; 19(1):237-54.
[Mol Endocrinol. 2005]Mol Endocrinol. 2003 Mar; 17(3):318-32.
[Mol Endocrinol. 2003]J Mol Endocrinol. 2006 Feb; 36(1):201-20.
[J Mol Endocrinol. 2006]Mol Endocrinol. 2005 Oct; 19(10):2610-23.
[Mol Endocrinol. 2005]Mol Cell Endocrinol. 2008 Jan 16; 281(1-2):27-36.
[Mol Cell Endocrinol. 2008]J Biol Chem. 2002 Nov 15; 277(46):44408-16.
[J Biol Chem. 2002]EMBO J. 1999 Jun 15; 18(12):3431-41.
[EMBO J. 1999]